The company has begun Phase Ib trial to find the optimal dosage.
Oramed Pharmaceuticals Inc. (Bulletin Board:ORMP); DAX:OJU) has begun Phase Ib clinical trials for its oral insulin capsule. This trial's goal is to find the optimal dosage for the formulation of the proprietary oral insulin delivery technology. The study utilizes healthy human volunteers in order to determine the final formulation of the oral insulin product. This trial follows the successful Phase Ia trial, which was also conducted on healthy volunteers
The Jerusalem-based company is developing an oral insulin gel capsule for the treatment of diabetes. Most insulin is currently delivered by injection. The company recently launched a second product - an insulin inhalant. Oramed’s product includes enzymes, which are attached to the insulin and protect it from the digestive juices. The technology was developed at Hadassah Medical Organization by the mother of Oramet CEO Nadav Kidron, Dr. Miriam Kidron, and by Dr. Hanoch Bar-On.
Oramed has a market cap of $13 million. The share was unchanged in Frankfurt today at €0.155, and rose 5% to $0.31 at the opening on the Bulletin Board.
Published by Globes [online], Israel business news - www.globes-online.com - on January 24, 2008
© Copyright of Globes Publisher Itonut (1983) Ltd. 2008